Joseph Pareti

Contributor   in
Emerging Technologies  

I like Machine Learning (ML) applications for Bioscience and Engineering. ML is what I have been doing since 2018. Prior to that, I worked MANY years for various Companies as an R&D Engineer, Application Engineer, CAE & HPC Consultant, and Pre-Sales solutions architect. My interests include learning and coding on one side, and evaluating how to found or co-found a business.

tags:  

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Posts by this author

Applying AI and HPC to Drug Design: a Survey of R&D Work

   428
Applying AI and HPC to Drug Design: a Survey of R&D Work

The motivation for this report

In 2018, while at Supercomputing in Dallas I had a couple key encounters that profoundly influenced my work path ever since:

FIRST. At Nvidia, I saw a presentation about ANI1, to approximate molecules energy using deep learning. This is a precondition to accurately calculate dynamic and chemical parameters. The result is a dramatic reduction of time to solution, while achieving the same or better accuracy than using the exact numerical method. Five (yes, 5) orders of magnitude faster time-to-solution are demonstrated on a 54 atoms molecule than using Density Functional Theory. The neural network approximates DFT output data. But molecules vary in size while the input to the network must be of constant size, so the authors extended Behler-Parrinello functions and created special vectors that describe the input to the network.